HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: 292/6/F1710    most recent 00505.2006v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (2) Citing Articles via Google Scholar Google Scholar Articles by Yang, C. Articles by Kaushal, G. P. Search for Related Content PubMed PubMed Citation Articles by Yang, C. Articles by Kaushal, G. P.

Mcl-1 is downregulated in cisplatin-induced apoptosis, and proteasome inhibitors restore Mcl-1 and promote survival in renal tubular epithelial cells

Departments of ¹Medicine and ²Biochemistry, University of Arkansas for Medical Sciences, Little Rock; and ¹Central Arkansas Veterans Healthcare System, Little Rock, Arkansas

Submitted 18 December 2006 ; accepted in final form 14 February 2007

Mcl-1 is an antiapoptotic member of the Bcl-2 family that plays an important role in cell survival. We demonstrate that proteasome-dependent regulation of Mcl-1 plays a critical role in renal tubular epithelial cell injury from cisplatin. Protein levels of Mcl-1 rapidly declined in a time-dependent manner following cisplatin treatment of LLC-PK₁ cells. However, mRNA levels of Mcl-1 were not altered following cisplatin treatment. Expression of other antiapoptotic members of the Bcl-2 family such as Bcl-2 and BclxL was not affected by cisplatin treatment. Cisplatin-induced loss of Mcl-1 occurs at the same time as the mitochondrial release of cytochrome c, activation of caspase-3, and initiation of apoptosis. Treatment of cells with cycloheximide, a protein synthesis inhibitor, revealed rapid turnover of Mcl-1. In addition, treatment with cycloheximide in the presence or absence of cisplatin demonstrated that cisplatin-induced loss of Mcl-1 results from posttranslational degradation rather than transcriptional inhibition. Overexpression of Mcl-1 protected cells from cisplatin-induced caspase-3 activation and apoptosis. Preincubating cells with the proteasome inhibitor MG-132 or lactacystin not only restored cisplatin-induced loss of Mcl-1 but also resulted in an accumulation of Mcl-1 that exceeded basal levels; however, Bcl-2 and BclxL levels did not change in response to MG-132 or lactacystin. The proteasome inhibitors effectively blocked cisplatin-induced mitochondrial release of cytochrome c, caspase-3 activation, and apoptosis. These studies suggest that proteasome regulation of Mcl-1 is crucial in the cisplatin-induced apoptosis via the mitochondrial apoptotic pathway and that Mcl-1 is an important therapeutic target in cisplatin injury to renal tubular epithelial cells.

acute kidney injury; Bcl-2 family

This article has been cited by other articles:

				K. Bray, H.-Y. Chen, C. M. Karp, M. May, S. Ganesan, V. Karantza-Wadsworth, R. S. DiPaola, and E. White Bcl-2 Modulation to Activate Apoptosis in Prostate Cancer Mol. Cancer Res., September 1, 2009; 7(9): 1487 - 1496. [Abstract] [Full Text] [PDF]

				Z. Yang, D. Gagarin, G. St. Laurent III, N. Hammell, I. Toma, C.-a. Hu, A. Iwasa, and T. A. McCaffrey Cardiovascular Inflammation and Lesion Cell Apoptosis: A Novel Connection via the Interferon-Inducible Immunoproteasome Arterioscler Thromb Vasc Biol, August 1, 2009; 29(8): 1213 - 1219. [Abstract] [Full Text] [PDF]

				C. L. Hann, V. C. Daniel, E. A. Sugar, I. Dobromilskaya, S. C. Murphy, L. Cope, X. Lin, J. S. Hierman, D. L. Wilburn, D. N. Watkins, et al. Therapeutic Efficacy of ABT-737, a Selective Inhibitor of BCL-2, in Small Cell Lung Cancer Cancer Res., April 1, 2008; 68(7): 2321 - 2328. [Abstract] [Full Text] [PDF]